Premium
Importin subunit alpha‐2 is identified as a potential biomarker for non‐small cell lung cancer by integration of the cancer cell secretome and tissue transcriptome
Author(s) -
Wang ChunI.,
Wang ChihLiang,
Wang ChihWei,
Chen ChiDe,
Wu ChihChing,
Liang Ying,
Tsai YingHuang,
Chang YuSun,
Yu JauSong,
Yu ChiaJung
Publication year - 2010
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.25568
Subject(s) - lung cancer , biology , cancer research , cancer , adenocarcinoma , carcinoembryonic antigen , biomarker , immunohistochemistry , karyopherin , pathology , immunology , medicine , gene , biochemistry , cell nucleus , genetics , nuclear transport
The cancer cell secretome may contain potentially useful biomarkers. In this study, we integrated the profiles of secreted proteins in lung cancer cell lines with mRNA expression levels from pulmonary adenocarcinoma tissue, with a view to identify effective biomarkers for non‐small cell lung cancer (NSCLC). Among the novel candidates isolated, importin subunit alpha‐2 (also known as karyopherin subunit alpha [KPNA]‐2), was selected for further validation. Immunohistochemical staining revealed overexpression of KPNA2 in the nuclei of tumor cells, compared with adjacent normal cells. A sandwich ELISA assay developed to detect KPNA2 levels in serum samples showed significantly higher serum KPNA2 in NSCLC patients than in healthy controls. A combination of serum KPNA2 and carcinoembryonic antigen displayed higher diagnostic capacity than either marker alone. Importantly, protein levels of KPNA2 in pleural effusion from NSCLC patients were also significantly higher than those from non‐lung cancer. Moreover, knockdown of KPNA2 inhibited the migration ability and viability of lung cancer cells. Our results collectively suggest that integration of the cancer cell secretome and transcriptome datasets provides an efficient means of identifying novel biomarkers for NSCLC, such as KPNA2.